Type 2 Diabetes

Insulin glargline-aglr is the second approved interchangeable biosimilar insulin product to insulin glargine indicated to improve glycemic control in patients with diabetes mellitus.

Kim Zuber, MS, PA-C, and Jane Davis, DNP, provide perspective on the recent consensus statement on management of chronic kidney disease from the American Diabetes Association and the Kidney Disease Improving Global Outcomes group.

A Cedars-Sinai-led analysis of data from the PROCEED study provides insight into risk factors and clinical predictors of diabetes among a cohort of adult patients with chronic pancreatitis.

Dr Elaine M. Apperson shares diabetes prevention strategies and mitigating disease complications in the pediatric population as well as advice for health care practitioners managing the disease.

Elaine M. Apperson, MD, addresses early intervention and technologies for monitoring type 1 diabetes for disease management.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

An expert pediatric endocrinologist discusses raising awareness among pediatricians about type 1 diabetes.

Dr Elaine M. Apperson provides insight on when to refer patients with type 1 diabetes to pediatric endocrinology and comments on offering sibling antibody screening.

In this column, Gregory Weiss, MD, reviews recent data suggesting lipid biomarkers could be used to identify patients at increased risk of developing diabetic neuropathy later in life.

Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

The late-breaking findings presented at AHA 2022 suggest the incidence of CV events was not lower among patients who received pemafibrate compared with those who received placebo.

In this column, Gregory Weiss, MD, provides perspective on a recent study providing evidence in support of metformin as a potential therapeutic option for treatment of atrial fibrillation.

A new user, active comparator analysis suggests use of GLP-1 receptor agonists and SGLT2 inhibitors was associated with a reduced risk of severe COPD exacerbations compared with use of sulfonylureas among people with diabetes and COPD.

An analysis of data from the Netherlands Epidemiology and Obesity study suggests those who engaged in physical activity in the afternoons or evening conferred the greatest benefit in terms of insulin resistance.

Elaine M. Apperson, MD, reviews screening guidelines for the management of type 1 diabetes.

An expert pediatric endocrinologist addresses awareness of family history of type 1 diabetes as well as differentiating within type 1 and type 2 disease.

An analysis of NHANES data from adults with diabetes provides insight into the impact of food insecurity and poor diet quality on diabetes management.

An analysis of real-world data from a single medical center is providing insight into the effects of off-label GLP-1 receptor agonist and SGLT2 inhibitor use in people with type 1 diabetes.

Welcome back to Crisis Point. A special episode focuses on the issue of insulin accessibility and affordability in the United States, with four experts in the diabetes arena weighing in on the topic.

A 6-month trial comparing a low-carbohydrate diet against usual diet is providing new insight into the effects of adherence to such an approach on people with prediabetes or type 2 diabetes with elevated, but untreated HbA1c.

Dr Elaine M. Apperson defines each stage of type 1 diabetes and how progression may present in pediatric patients.

Elaine M. Apperson, MD, reviews the prevalence and risk factors in the pediatric population for type 1 diabetes.

An analysis of data from the FIDELITY program suggests use of finerenone reduced negative heart failure outcomes in people with diabetes and chronic kidney disease, regardless of baseline kidney function.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ongoing GLP-1 RA shortage and whether or not celebrities using these agents for weight loss is a real issue in the community as well as provide insight into their top takeaways from the ADA/KDIGO consensus report.

A systematic review and meta-analysis leveraging data from nearly 200 studies provides a comprehensive overview of factors associated with increased risk of diabetic ketoacidosis at onset of type 1 diabetes among pediatric populations.

National coverage of MTMs for diet-related diseases may be associated with 1.6 million averted hospitalizations and net cost savings of $13.6 billion annually.

An analysis of 2021 NHIS data suggests 16.5% of adult insulin users in the US reported rationing insulin in the past year, with results providing additional insight into characteristics associated with increased likelihood of rationing, including diabetes type, patient age, racial/ethnic background, and insurance type.

The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.

In an interview at the 6th annual Cardio-Endo-Renal Collaborative from Physicians' Education Resource, Amy Mottl, MD, provides perspective on recent data from the CURE-CKD registry and problems facing nephrologists as they cope with an increasing prevalence of diabetes.